Genomic Vision (GV) - Product Pipeline Analysis, 2018 Update
June 2018
34
About the Report
About the Report
Summary
Genomic Vision (Genomic) is a molecular diagnostics and technology company that develops and commercializes diagnostic tests for genetic diseases and cancers. The company's portfolio comprises tests for breast cancer and colon cancer, diagnostic solution for facio-scapulo-humeral muscular dystrophy; and tools for identifying and characterizing rearrangements which affect the BRCA1 and BRCA2 genes. Its diagnostic tests are based on DNA molecular combing technology. Genomic's technology finds application in monitoring both spatial and temporal characteristics of DNA replication in a single experiment and identification of structural variations at any position within the genome. It conducts research studies on large genomic rearrangements. Genomic is headquartered in Paris, France.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Genomic Vision
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Genomic Vision, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies
Companies
Qiagen Marseille SA
Adocia SAS
Genfit SA
IntegraGen SA
Table of Contents
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Genomic Vision Company Overview 4
Genomic Vision Company Snapshot 4
Genomic Vision Pipeline Products and Ongoing Clinical Trials Overview 4
Genomic Vision-Pipeline Analysis Overview 7
Genomic Vision-Key Facts 7
Genomic Vision-Major Products and Services 8
Genomic Vision Pipeline Products by Development Stage 9
Genomic Vision Ongoing Clinical Trials by Trial Status 11
Genomic Vision Pipeline Products Overview 13
BRCACombing Test 13
BRCACombing Test Product Overview 13
DNA Combing Based Test-Neurological Disorder 14
DNA Combing Based Test-Neurological Disorder Product Overview 14
FiberVision Automated Scanner 15
FiberVision Automated Scanner Product Overview 15
High-Throughput Scanner 16
High-Throughput Scanner Product Overview 16
HPV Combing Test 17
HPV Combing Test Product Overview 17
HPV Combing Test Clinical Trial 18
Lynch Syndrome Test 19
Lynch Syndrome Test Product Overview 19
Telomere Length Assay 20
Telomere Length Assay Product Overview 20
Genomic Vision-Key Competitors 21
Genomic Vision-Key Employees 22
Genomic Vision-Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Genomic Vision, Recent Developments 24
Apr 24, 2018: Genomic Vision Invited to Present FiberVision Platform at the NIST-FDA Genome Editing Workshop in Gaithersburg (Maryland) 24
Jan 17, 2018: Genomic Vision: 2017 Annual Revenue from Sales: +36% to EUR2.1 Million 24
Oct 24, 2017: Genomic Vision: Revenue from Sales for the First 9 Months of 2017 up 103% to EUR1.3 Million 25
Oct 18, 2017: Genomic Vision: Report of the LSR R&D Day 26
Oct 11, 2017: Genomic Vision Presented the Interim Results of Its Clinical Trial in Cervical Cancer Screening at the Eurogin Annual Congress 26
Sep 11, 2017: Genomic Vision: High Attendance at the 1st US Satellite Symposium on Molecular Combing 27
Jul 27, 2017: Genomic Vision: Molecular Combing Featured in an Oral Presentation on CRISPR/Cas9 Gene Editing at the 3rd CSHL Meeting in New York 27
Jul 25, 2017: Genomic Vision: First half 2017 results 28
Jul 12, 2017: Genomic Vision: The Cologne Center for Genetics, a Major European Core Facility in Genetic Analysis, Adopts the Molecular Combing Technology 29
Jun 19, 2017: Genomic Vision Inks Chinese Distribution Deal with APG Bio 30
Appendix 31
Methodology 31
About GlobalData 33
Contact Us 33
Disclaimer 34
List of Figure
List of Figures
Genomic Vision Pipeline Products by Equipment Type 5
Genomic Vision Pipeline Products by Development Stage 9
Genomic Vision Ongoing Clinical Trials by Trial Status 11
List of Table
List of Tables
Genomic Vision Pipeline Products and Ongoing Clinical Trials Overview 4
Genomic Vision Pipeline Products by Equipment Type 5
Genomic Vision Pipeline Products by Indication 6
Genomic Vision Ongoing Clinical Trials by Trial Status 6
Genomic Vision, Key Facts 7
Genomic Vision, Major Products and Services 8
Genomic Vision Number of Pipeline Products by Development Stage 9
Genomic Vision Pipeline Products Summary by Development Stage 10
Genomic Vision Ongoing Clinical Trials by Trial Status 11
Genomic Vision Ongoing Clinical Trials Summary 12
BRCACombing Test-Product Status 13
BRCACombing Test-Product Description 13
DNA Combing Based Test-Neurological Disorder-Product Status 14
DNA Combing Based Test-Neurological Disorder-Product Description 14
FiberVision Automated Scanner-Product Status 15
FiberVision Automated Scanner-Product Description 15
High-Throughput Scanner-Product Status 16
High-Throughput Scanner-Product Description 16
HPV Combing Test-Product Status 17
HPV Combing Test-Product Description 17
HPV Combing Test-Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution 18
HPV Combing Test-Integration of Oncogenic HPV DNA in Czech Republic 18
Lynch Syndrome Test-Product Status 19
Lynch Syndrome Test-Product Description 19
Telomere Length Assay-Product Status 20
Telomere Length Assay-Product Description 20
Genomic Vision, Key Employees 22
Glossary 32
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.